Merck's Keytruda Surge: A Boost Amid Acquisition Costs

Merck's Q1 sales surpassed expectations, driven by strong demand for Keytruda. Despite acquisition-related losses, investors focus on growth as Keytruda's patent end nears. New products in the pipeline promise potential, with Merck projecting increased 2026 profits, excluding its planned Terns Pharmaceuticals acquisition impact.

Merck exceeded first-quarter sales forecasts on Thursday, thanks in part to strong demand for its established cancer treatment, Keytruda. This comes as the company grapples with acquisition-related costs, particularly a $3.62-per-share charge tied to its Cidara Therapeutics acquisition, sparking a 5% rise in its stock during premarket trading.

The pharmaceutical giant is working towards long-term growth by capitalizing on its late-stage development pipeline. Merck's Keytruda sales saw a 12% increase, amounting to $8 billion, as the company strategizes to lower its dependence on the drug, which will soon lose patent protection.

CEO Rob Davis expressed optimism about the 20 new products nearing launch, many with high-revenue potential. Despite the forecasted adjusted loss in the first quarter, Merck has revised its full-year earnings outlook upward, highlighting stable growth pathways albeit without reflecting its recent Terns Pharmaceuticals acquisition.